Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Evaluation of an Intervention for Optimizing Pregnant Women's Adherence to Maternal Multiple Micronutrients Supplements

8 giugno 2026 aggiornato da: Nutrition International
In collaboration with the Federal Government of Nigeria and Bauchi State, Nutrition International (NI) conducted a three-year implementation research study to assess whether adherence solutions - developed through a human-centered designed (HCD) approach - could improve adherence to multiple micronutrient supplementation (MMS) among pregnant women in Nigeria. These set of adherence solutions focused on strengthening the capacity of healthcare workers and community members, improving nutrition counselling within antenatal care, and engaging pregnant women' family members to support consistent MMS intake.

Panoramica dello studio

Stato

Completato

Condizioni

Descrizione dettagliata

Research has shown that antenatal multiple micronutrient supplementation (MMS), a daily dose of 15 vitamins and minerals, is just as effective as iron and folic acid supplementation (IFAS) in preventing maternal anaemia, more effective at improving birth outcomes and is safe for mothers and babies.

In 2020, the World Health Organization (WHO) released an updated guidance recommending that implementation research (IR) be conducted in settings where the transition from IFAS to MMS is being considered in low- and middle- income countries. IR can help countries understand how to best design and implement effective intervention in real-life settings and can be used to identify and investigate challenges that prevent effective implementation.

In line with the WHO's recommendation, in 2021, the Nigeria Federal Ministry of Health approved the use of MMS during pregnancy and called for implementation research (IR) in the updated National Guidelines for the Prevention and Control of Micronutrient Deficiencies in Nigeria.

Based on national stakeholders' identification of a critical need for context-specific implementation evidence, efforts focused on understanding how MMS can be effectively delivered, accepted, and adhered to within the Nigerian health system, particularly in light of the implementation bottlenecks and adherence gaps previously documented in IFAS programs.

This IR project aims to evaluate implementation approaches on optimizing pregnant women's adherence to MMS. One of the components of this IR project is an outcome evaluation - the focus of this protocol - that seeks to answer the following research questions:

Primary research questions:

• Does implementation of these implementation approaches increase pregnant women's adherence to MMS?

Secondary research questions:

  • Are the implementation approaches acceptable to key stakeholders?
  • Does implementation of the implementation approaches increase the quality of care/nutrition counseling in ANC?

The implementation approaches focused on:

  • Strengthening the capacity building of healthcare workers and community members
  • Improving nutrition counselling integrated into ANC delivery with an emphasis on MMS adherence
  • Engaging pregnant woman's family members (husbands) and influential community members to support maternal health and nutrition

An outcome evaluation was completed using a cluster randomized controlled trial (cRCT) with cross-sectional baseline (prior to the introduction of the implementation approaches) and endline (approximately 2 years after the introduction of the introduction of the implementation approaches) surveys among pregnant women, their husbands and healthcare workers (HCWs) across the three Local Government Areas (LGAs) in Bauchi State. MMS was integrated into routine ANC across the state prior to the baseline assessment.

Nutrition International worked closely with the Bauchi state government to select 3 LGAs (Dass, Ganjuwa and Giade) representing the north, central and southern parts of the state. This decision was made taking into consideration state representation key criteria such as religious demographic, ANC attendance, security, IFA utilization and socio-economic distribution. These LGAs comprise a total of 42 wards all of which were designated as study clusters for the intervention and control arms. Out of these 42 wards, a simple random selection was used to randomly allocate 22 wards to the intervention arm and 20 to the control arm across the three target LGAs:

  • Control arm: Eligible pregnant women in these study sites receive MMS as part of their standard ANC.
  • Intervention arm: Eligible pregnant women in these study sites receive MMS alongside the implementation approaches as part of their standard ANC.

A third observational arm was selected from a separate LGA where MMS had not been introduced and IFAS continued to be the standard of care to help contextualise differences between the intervention and control arms.

Quantitative and qualitative data were collected from participants through interviewer-administered questionnaires and focus group discussions. The study measured adherence through several methods including self-reported daily consumption, average consumption rate over a three-month period, and a physical pill count by the data collector. Difference-in-difference analysis will be used to assess whether the implementation approaches increased MMS adherence at endline. Descriptive statistics will be used to determine whether the adherence solutions are acceptable to healthcare workers, pregnant women, and their husbands.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

2601

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Bauchi
      • Dass, Bauchi, Nigeria
        • Public health facilities in Dass
      • Ganjuwa, Bauchi, Nigeria
        • Public health facilities in Ganjuwa
      • Giade, Bauchi, Nigeria
        • Public health facilities in Giade

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

Descrizione

Inclusion Criteria:

Pregnant/post-partum women

  • Women of reproductive age (15-49 years of age)
  • Pregnant or up to 3 months post-partum women
  • Having reportedly received at least one MMS bottle at least 30 days before start of data collection from a participating public health facility-
  • Provide consent for participation

Health Care Workers (HCWs)

  • HCWs providing ANC services including MMS and IFAs to pregnant women at the selected health facilities

Husbands

  • Husbands of the enrolled pregnant women At endline, the same criteria apply.

Exclusion Criteria:

  • Anemic pregnant women

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Braccio di controllo
Sperimentale: Intervention Arm
Eligible pregnant women received implementation approaches
Implementation approaches are human-centered designed strategies aimed at optimizing pregnant women's daily adherence to MMS.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Adherence to MMS
Lasso di tempo: At baseline and approximately 2 years after (endline)

Defined as "when pregnant women consume the right dose of multiple micronutrient supplementation (MMS) at the right time throughout pregnancy".

Measured through self-reported daily consumption, self-reported average consumption rate over a three-month period, and pill count.

At baseline and approximately 2 years after (endline)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Acceptability
Lasso di tempo: At baseline and approximately 2 years after (endline)

Defined as stakeholders' attitude towards MMS and its introduction as part of ANC. Assessed through surveys (Likert scale).

The Likert scale is a 5 point scale quantifying attitudes from "strongly agree" to "strongly disagree".

At baseline and approximately 2 years after (endline)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Babajide Adebisi, Nutrition International
  • Investigatore principale: Jennifer Busch Hallen, Nutrition International

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

7 marzo 2024

Completamento primario (Effettivo)

26 maggio 2025

Completamento dello studio (Effettivo)

26 maggio 2025

Date di iscrizione allo studio

Primo inviato

14 gennaio 2025

Primo inviato che soddisfa i criteri di controllo qualità

8 giugno 2026

Primo Inserito (Effettivo)

12 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Descrizione del piano IPD

Published IPD will be shared upon reasonable request

Periodo di condivisione IPD

May 2026 for 3 years.

Criteri di accesso alla condivisione IPD

Access to the data will be restricted to the data collectors and study team, both of whom will sign a confidentiality agreement. When transmitting this data to investigators approved for this study, anonymized datasets will then be sent by encrypted zipped file in Stata format, The password to access these files will be communicated separately using email. The encryption keys will be transferred in the same way to co-investigators, if and as needed.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Implementation Approaches

Sottoscrivi